Topics in Anti-Cancer Research.
- 1st ed.
- 1 online resource (817 pages)
- Topics in Anti-Cancer Research ; v.1 .
- Topics in Anti-Cancer Research .
Intro -- CONTENTS -- FOREWORD -- List of Contributors -- Targeted Cancer Therapy: The Roles Played by Antibody-Drug and Antibody-Toxin Conjugates -- 1. INTRODUCTION -- 2. IMMUNOTOXINS -- 2.1. Pseudomonas Exotoxin-Based Immunotoxins -- 2.2. Pseudomonas Exotoxin-Based ITs in Treating Solid Tumors -- 2.3. Diphtheria Toxin-Based Immunotoxins -- 2.4. Ribosome Inactivating Proteins-Based Immunotoxins -- 2.4.1. Ricin -- 2.4.2. Recombinant constructs of RIP I toxins -- 2.5. Ribonucleases-Based IT -- 2.6. Proapoptotic Proteins Used As Targeted Immunotoxins/Chimeric Proteins -- 2.7. Current & -- Future Developments of ITs -- 3. ANTIBODY-DRUG CONJUGATES -- 3.1. DNA Interacting Agents-Calicheamicins -- 3.2. DNA Interacting Agents-Duocarmycins -- 3.3. DNA Interacting Agents-Pyrrolo[1,4]Benzodiazepines -- 3.4. Tubulin Interacting Agents-Auristatins -- 3.5. Tubulin Interacting Agents-Maytansinoids -- 3.6. Other Anticancer Drugs Conjugated to mAbs -- 4. CURRENT AND FUTURE DEVELOPMENTS OF ADC -- DISCLOSURE -- CONFLICTS OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Targeting Cell Surface Nucleolin in Cancer -- INTRODUCTION -- CELL SURFACE LOCALIZATION OF NCL -- LIGANDS OF CELL SURFACE NCL -- CELL SURFACE NCL-DEPENDENT LIGAND SPECIFIC INTERNALIZATION -- CELL SURFACE NCL AND SIGNALING COMPLEXES -- TARGETING CELL SURFACE NCL -- CELL SURFACE NCL AS BIOMARKER FOR CANCER -- PATENTS RELATED TO NCL -- CURRENT & -- FUTURE DEVELOPMENTS -- DISCLOSURE -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Anticancer Agents Targeting Tubulin -- 1. INTRODUCTION -- 2. MICROTUBULE DESTABLIZERS -- 2.1. Colchicine -- 2.2. Combretastatin A-4 (CA-A4) -- 2.3. Chalcones -- 2.4. Phenstatins -- 2.5. Podophyllotoxin -- 2.6. Vinca Alkaloids -- 2.7. Other Tubulin Polymerization Inhibitors -- 3. MICROTUBULE STABLIZERS -- 3.1. Taxol®. 3.2. Other Tubulin Depolymerization Inhibitors -- Drugs Bind to Microtubule-Associated Proteins (MAPs) -- Peripheral Neuropathy Induced by Anti Mitotic Agents [177] -- Role of β-Tubulin Isotypes in Drug Binding [178] -- 4. RECENT PATENTS -- 4.1. Research Corporation Technologies Patents -- 4.2. Brandeis University Patents -- 4.3. Tuse et al. Patents -- 4.4. Pinney et al. Patents -- 4.5. Aventis Pharma Patents (2001) -- 4.6. Davis et al. Patents -- 4.7. Aventis Pharma Patents (2003) -- 4.8. Chang et al. Patents -- 4.9. Hadfield et al. Patents -- 4.10. Rigel Pharmaceuticals Patents -- 4.11. NIH Patents -- 4.12. Cytopia Pty Ltd Patents -- 4.13. Galemmo et al. Patents -- 4.14. Pettit et al. Patents -- 4.15. Patent by Aneja et al. -- 4.16. Wyeth Holding Corporation Patents -- 4.17. Champions Biotechnologypatents -- 4.18. Bionomics Ltd. Patents -- 4.19. Janssen Pharmaceutica Patents -- 4.20. Exonhit Patents -- 4.21. Centre National De La Recherche Scientifique Patents -- 4.22. Development Centre of Biotechnology Patents -- 4.23. Y M Biosciences Pty Ltd. Patents -- 4.24. Patents by Gangjee et al. -- 4.25. Thorson et al. Patents -- 4.26. Bionomics Ltd. Patents -- 4.27. Chen et al. (2014) -- 4.28. Wang et al. (2014) -- 4.29. Burns et al. (2014) -- 4.30. Papadopoulos et al. (2014) -- 4.31. Richter (2014) -- 4.32. Chaplin et al. (2014) -- 4.33. Angibaud et al. (2015) -- 5. MICROTUBULE STABILIZERS/DESTABLIZERS IN CLINICAL TRIALS -- 6. CURRENT & -- FUTURE DEVELOPMENTS -- DISCLOSURE -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Resveratrol in Malignant Hemopathies -- 1. INTRODUCTION -- 2. MECHANISMS OF ACTION -- Origin and Effects -- Cell Penetration and Location -- Cell Phenotype Modulation -- Antioxidant Properties -- Inhibition of DNA Synthesis and Apoptosis Induction -- Cellular Pathways Influenced by Resveratrol. Intervention on Epigenetic Malignization -- Effect on Multidrug Resistance -- Immunotherapeutic Potential -- Mitochondrial Superoxide -- Hormetic Dose Response -- Action on the Cancerous/Normal Cells -- The Regulation of miRNAs -- Comparison With Other Natural Products -- Concluding -- 3. RESVERATROL ACTIONS IN HEMATOLOGICAL MALIGNANCIES -- Myeloid Malignancies -- Lymphoid Malignancies -- Concluding -- 4. PHARMACOKINETICS, METABOLISM AND BIOAVAILABILITY PROBLEMS -- 5. RESVERATROL CO-ADMINISTRED WITH OTHER ANTILEUKEMIC AGENTS -- 6. TOXICITY -- 7. NEW PATENTS -- 8. CURRENT & -- FUTURE DEVELOPMENTS -- CONCLUSION -- DISCLOSURE -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Cancer Immunotherapy: The Share of Cytokines and Chemokines -- INTRODUCTION -- CYTOKINES: GENERAL PROPERTIES AND ROLE IN CANCER IMMUNOTHERAPY -- 1. THE INTERFERONS (IFNS) -- Type I IFNs -- 1.2. Type II Interferons -- 1.3. Type III Interferons -- 2. INTERLEUKIN-2 -- 3. IL-2 RELATED CYTOKINES -- 3.1. Interleukin 7 -- 3.2. Interleukin 15 -- 3.3. Interleukin 21 -- 4. OTHER CYTOKINES WITH CLINICAL SIGNIFICANCE -- 4.1. Interleukin-6 -- 4.2. Interleukin-12 -- 4.3. Interleukin-18 -- 4.4. Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) -- Chemokines: General Features -- Chemokines in Cancer Immunotherapy -- CONCLUSION -- CURRENT & -- FUTURE DEVELOPMENTS -- CONFLICT OF INTEREST -- DISCLOSURE -- ACKNOWLEDGEMENTS -- REFERENCES -- Molecular Hybrids with Anticancer Activity -- 1. INTRODUCTION -- 1. Tubulin Inhibitors Based Anticancer Hybrids -- i. Chalcone based hybrids [24 - 30] -- ii. Combretastatins based hybrids [31 - 37] -- iii. Colchicine based Hybrids [38 - 45] -- iv. Podophyllotoxin Based Hybrids [46 - 49] -- v. Taxol based Hybrids [50 - 51] -- vi. Vinca Alkaloids [54 - 55] -- 2. Isatin Based Hybrids -- 3. Coumarin Based Hybrids -- 4. Steroidal Hybrids. 5. Pyrrolo [2, 1-c][1, 4]-Benzodiazepine (PBD) Based Hybrids -- 6. Non-Classified Hybrids: Fig. (12) Represents the Structure of Non-Classified Anticancer Hybrids [112 - 138] -- 2. PATENT SURVEY -- (A) Israel et al. Patent (1990) -- (B) Mark et al. Patent (1995) -- (C) Xia et al. Patent (2000) -- (D) Kamal et al. Patent (2004) -- (E) Kamal et al. Patent (2004) -- (F) Kamal et al. Patent (2008) -- (G) Kamal et al. Patent (2008) -- (H) Kamal et al. Patent (2008) -- (I) Kamal et al. Patent (2009) -- (J) Kamal et al. Patent (2010) -- (K) Kamal et al. Patent (2011) -- (L) Kamal et al. Patent (2011) -- (M) Kamal et al. Patent (2011) -- (N) Kamal et al. Patent (2011) -- (O) Kamal et al. Patent (2011) -- (P) Wu et al. Patent (2011) -- (Q) Kamal et al. Patent (2012) -- (R) Kamal et al. Patent (2012) -- (S) Kamal et al. Patent (2012) -- (T) Kamal et al. Patent (2012) -- (U) Kamal et al. Patent (2012) -- (V) Kamal et al. Patent (2012) -- (W) Kamal et al. Patent (2013) -- (X) Kamal et al. Patent (2013) -- (Y) Change et al. Patent (2013) -- (Z) Recently Published Patents In 2014 -- (a) Sashidhara et al. patent -- (b) Bierbach et al. Patent -- CURRENT & -- FUTURE DEVELOPMENTS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- DISCLOSURE -- REFERENCES -- On the Use of Gold Macro-Rods and Ultrasound as a Hyperthermia Cancer Treatment: Experimental Results on Ehrlich Tumor in Mus musculus Mice -- 1. INTRODUCTION -- 2. RESULTS AND DISCUSSION -- 2.1. Methodology -- 2.2. Results and Discussions -- 3. CURRENT & -- FUTURE DEVELOPMENTS -- AUTHOR CONTRIBUTIONS -- CONFLICTS OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Circulating and Local Estrogen Concentrations are Protective against Breast Cancer in Obese Women -- INTRODUCTION -- PATHOGENETIC MECHANISMS AS LINKS BETWEEN OBESITY AND BREAST CANCER RISK -- Obesity Related Insulin Resistant States. Obesity Related Alterations in the Sexual Steroid Production -- Inflammatory and Metabolic Dysfunctions of Adipose Tissue in Visceral Obesity -- PROTECTIVE EFFECTS OF ESTROGEN AGAINST OBESITY AND OBESITY ASSOCIATED ALTERATIONS -- Anti-Obesity Effects of Estrogen -- Anti-atherogenic and Anti-hypertensive Effects of Estrogen -- Antidiabetogenic Impacts of Estrogen -- Regulation of Adipokine Secretion, Inflammatory Reactions and Growth Factor Activity by Estrogen -- CORRELATIONS BETWEEN GRADE AND DISTRIBUTION OF ADIPOSITY AND BREAST CANCER RISK -- LIFELONG CHANGES IN THE ESTROGEN LEVEL OF WOMEN AND THEIR RELATION TO OBESITY AND BREAST CANCER RISK -- Obesity Associated Hormonal Alterations in Childhood and Adolescence and their Prediction for Breast Cancer Risk -- Controversial Associations between Obesity Related Anovulatory, Irregular Menstrual Cycles and Breast Cancer Risk in Premenopausal Women -- Correlations between Reproductive Data and Obesity-Associated Breast Cancer Risk in Premenopausal Women -- Correlations between Postmenopausal Obesity and Breast Cancer Risk in Women -- DEFENSIVE ESTROGEN SYNTHESIS OF ADIPOCYTES IN THE MICROENVIRONMENT OF BREAST CANCER -- Aromatase Synthesis in Breast Tissue and Breast Malignancies -- Inconsistent, Transient Anticancer Capacity of Antiestrogens and the Apparent Antiestrogen Resistance of Tumors -- Searching for the Mechanisms of Antiestrogen Resistance -- The Key for the Transiently Successful Aromatase Inhibitor Therapy of Breast Cancer -- EFFECTS OF EXOGENOUS HORMONE TREATMENT AND ENVIRONMENTAL ENDOCRINE DISRUPTORS ON BREAST CANCER RISK -- ESTROGEN THERAPY OF BREAST CANCER -- CONCLUSION -- CURRENT & -- FUTURE DEVELOPMENTS -- DISCLOSURE -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Recent Patents on Polymeric Nanosystems Applications for Anticancer Drug Delivery -- 1. INTRODUCTION. 1.1. Nanoparticles as Drug Carriers: General Considerations.